Darzalex Routine Boosts Charges of MRD Negativity in Newly Recognized, Transplant-Eligible Myeloma

Darzalex (daratumumab) plus Velcade (bortezomib), lenalidomide (Revlimid) and dexamethasone (D-VRd), adopted by autologous stem cell transplant (ASCT), D-VRd consolidation (therapy after ASCT) and Darzalex plus Revlimid (DR) upkeep improved charges of sustained minimal residual illness (MRD; measure of remaining most cancers cells after therapy) negativity in contrast with VRd induction, ASCT, VRd consolidation and Revlimid upkeep in transplant-eligible sufferers with newly recognized a number of myeloma, based on up to date information from the part 3 PERSEUS trial.

Findings, which had been introduced on the 2024 SOHO Annual Assembly, confirmed that amongst sufferers within the D-VRd arm (355 sufferers), 57.5% had been MRD destructive at a ten^-5 sensitivity (extraordinarily low) on the finish of consolidation vs 32.5% of sufferers within the VRd arm (354 sufferers). Within the experimental arm, the MRD-negative charges on the 10^-5 threshold at as much as 12 months, as much as 24 months, and as much as 36 months had been 65.1%, 72.1% and 74.6%, respectively. These respective charges had been 38.7%, 44.9% and 46.9% within the management arm.

At a ten^-6 sensitivity, the MRD-negativity charges (no detectable most cancers cells) within the D-VRd arm on the finish of consolidation, as much as 12 months, as much as 24 months and as much as 36 months had been 34.4%, 43.9%, 57.7% and 63.9%, respectively. Within the VRd arm, these respective charges had been 16.1%, 20.9%, 27.4% and 30.8%.

Moreover, 64.8% of sufferers within the D-VRd group sustained MRD negativity on the 10^-5 threshold for at the very least 12 months in contrast with 29.7% of sufferers in VRd arm. The charges of sufferers who sustained MRD negativity for at the very least 18 months at 10^-5 had been 59.4% and 25.1%, respectively. At a ten^-6 sensitivity, 47.3% of sufferers within the D-VRd arm sustained MRD negativity for at the very least 12 months vs 18.6% of sufferers within the VRd arm. The respective charges of sufferers who sustained MRD negativity for at the very least 18 months in these arms had been 42% and 15%.

“These information additional spotlight the good thing about D-VRd and DR upkeep as a brand new commonplace of look after transplant-eligible sufferers with newly recognized a number of myeloma,” presenting research writer Dr. Meletios A. Dimopoulos mentioned in the course of the presentation.

A New Remedy Choice for Transplant-Eligible, Newly Recognized Myeloma

On July 30, 2024, the FDA authorised D-VRd for induction and consolidation in sufferers with newly recognized a number of myeloma who’re candidates for ASCT, primarily based on prior information from PERSEUS.2

Earlier findings demonstrated that D-VRd decreased the danger of illness or dying by 58% in contrast with VRd alone. The 48-month progression-free survival (PFS; how lengthy a affected person with most cancers lives with out their illness getting worse) fee was 84.3% with D-VRd vs 67.7% with VRd.

PERSEUS Design and Targets

The part 3 research included sufferers 18 to 70 years of age with newly recognized a number of myeloma who had been eligible for ASCT.

Sufferers had been randomly assigned to a particular therapy previous to the beginning of induction remedy. Within the management arm, sufferers obtained VRd previous to ASCT. These within the experimental arm obtained Darzalex plus the identical VRd routine previous to transplant. Induction remedy was given for 4 28-day cycles. After ASCT, D-VRd or VRd had been administered on the similar dosages for 2 further cycles.

Throughout ongoing therapy, sufferers within the management arm obtained Revlimid till illness development. Within the experimental arm, ongoing remedy was primarily based on MRD standing; all sufferers initially obtained Darzalex plus Revlimid for no less than two years. Sufferers who had been MRD optimistic continued DR. Those that had been MRD destructive for at the very least 12 months and achieved an entire response (CR; when an individual’s illness can’t be detected by any assessments or examinations) or higher continued with Revlimid alone; they had been permitted to restart Darzalex in the event that they misplaced their CR with out progressive illness or turned MRD optimistic.

PFS served because the trial’s major end result. Secondary outcomes included general CR or higher fee, general MRD-negativity fee and general survival (OS; the time from the beginning of therapy when a affected person with most cancers remains to be alive).

Extra Up to date Knowledge from PERSEUS

Subgroup analyses confirmed that D-VRd improved MRD-negativity charges and sustained MRD-negativity charges in contrast with VRd throughout predefined teams.

The general stringent CR (sCR; a extra rigorous commonplace in contrast with conventional CR), CR, superb partial response (VGPR; most cancers shrank considerably however nonetheless current) and PR charges within the D-VRd arm had been 69.3%, 18.6%, 7.3% and 1.4%, respectively. These respective charges had been 44.6%, 25.4%, 19.2% and 4.5% within the management arm. The CR or higher fee was 87.9% within the D-VRd arm vs 70.1% within the VRd arm.

Within the D-VRd arm, the respective sCR, CR, VGPR and PR charges on the finish of induction had been 9.6%, 13%, 62.3% and 9.3%. After ASCT, these charges had been 10.7%, 17.2%, 57.5% and eight.7%, respectively. On the finish of induction, the sCR, CR, VGPR and PR charges had been 18.9%, 25.6%, 46.5% and 4.2%, respectively.

For the VRd arm, the sCR, CR, VGPR and PR charges on the finish of induction had been 7.1%, 14.1%, 51.4% and 18.1%, respectively. After ASCT, these respective charges had been 8.2%, 15.3%, 50% and 17.5%. Following consolidation, the sCR, CR, VGPR and PR charges had been 13%, 21.8%, 47.5% and 9.9%, respectively.

Amongst sufferers with high-risk illness, these handled with D-VRd (76 sufferers) achieved an MRD-negativity fee of 68.4% on the 10^-5 threshold and 57.9% on the 10^-6 threshold. These charges had been 47.4% and 30.8%, respectively, amongst sufferers with high-risk illness within the VRd arm (78 sufferers). Within the experimental arm, 48.7% of sufferers maintained MRD negativity at a ten^-5 sensitivity for at the very least 12 months and 30.3% remained MRD destructive on the 10^-6 threshold for at the very least 12 months. These respective charges had been 25.6% and 14.1% within the management arm.

D-VRd (44 sufferers) additionally trended towards improved PFS amongst sufferers with high-risk illness who achieved MRD negativity at a ten^-6 sensitivity in contrast with these handled with VRd (24 sufferers)

Amongst sufferers within the D-VRd arm who had been MRD optimistic on the finish of consolidation (88 sufferers), 60.2% turned MRD destructive on the 10^-5 threshold throughout upkeep in contrast with 40.5% of sufferers handled with VRd (121 sufferers). On the 10^-6 threshold, these charges had been 56.7% for D-VRd (134 sufferers) and 25.2% for VRd (155 sufferers). Amongst sufferers who turned MRD destructive at a ten^-5 sensitivity, 38.6% within the D-VRd arm had sustained MRD negativity vs 17.4% within the management arm. On the 10^-6 sensitivity, these respective charges had been 31.3% and 10.3%.

Reaching MRD negativity at a ten^-6 sensitivity was related to improved long-term outcomes in each arms. General, 65.1% of sufferers within the D-VRd arm reached MRD negativity on the 10^-6 threshold at any level in contrast with 32.2% of sufferers within the VRd arm.

“The share of sufferers reaching MRD negativity with D-VRd was considerably larger. This once more speaks in favor of administering [D-VRd] up-front so as to improve the variety of sufferers who will obtain MRD negativity, sustained MRD negativity, improved PFS and hopefully improved OS,” Dimopoulos concluded.

For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.